A multi-centre, randomized, double-blind, placebocontrolled, multiple-dose, 4-way cross-over study to evaluate the efficacy, safety, tolerability and pharmacokinetics of orally inhaled indacaterol salts (maleate, xinafoate and acetate) in patients with persistent asthma.

Trial Profile

A multi-centre, randomized, double-blind, placebocontrolled, multiple-dose, 4-way cross-over study to evaluate the efficacy, safety, tolerability and pharmacokinetics of orally inhaled indacaterol salts (maleate, xinafoate and acetate) in patients with persistent asthma.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 May 2016

At a glance

  • Drugs Indacaterol (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 12 Dec 2009 Actual patient number (27) added as reported by ClinicalTrials.gov.
    • 12 Dec 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 29 Jun 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top